• The Food and Drug Administration has approved Spark Therapeutics’ Luxturna.
  • The treatment would help those with Leber congenital amaurosis, a rare genetic retinal disease. It’s specifically approved for people who have a mutated RPE65 gene.
  • FDA Commissioner Scott Gottlieb said in a statement the approval marks another first in the field of gene therapy.

Read Full Article on CNBC >>